| Name | JI6 |
| Description | JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits c-Kit and JAK3, with IC50s of ∼500 and ∼250 nM, respectively. JI6 has research value in acute myeloid leukemia. |
| In vitro | JI6 (3-1000 nM; 1-4 days) inhibits MV4-11 cell viability dose-dependently with an IC50 of ∼25 nM. It also potently inhibits the viability of HCD-57 cells expressing FLT3-ITD, FLT3-D835Y, and FLT3-D835H (1-2000 nM; 48 h) with an IC50 of ∼40 nM, while showing no effect on parent HCD-57 or JAK2V617F expressing cells. Additionally, JI6 (100-500 nM; 24 h) induces apoptosis and cell cycle arrest, and (50-500 nM; 3 h) inhibits phosphorylation of FLT3, ERK, and Akt in HCD-57 cells expressing FLT3-ITD and FLT3-D835Y[1]. |
| In vivo | JI6 (15 mg/kg; i.p. daily for 3 weeks) inhibits the proliferation of HCD-57 expressing FLT3-D835Y in SCID mice and prolongs survival. JI6 (25 mg/kg; p.o. daily for 3 weeks) inhibits the myeloproliferative phenotype in FLT3-ITD knock-in mice. JI6 (100 mg/kg; a single i.p.) significantly inhibits FLT3 phosphorylation and downstream signal transduction in mice expressing FLT3-D835Y[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (11.74 mM), Sonication is recommended.
|
| Keywords | JI-6 | JI6 | JI 6 | FLT3 |
| Inhibitors Related | Gilteritinib | Regorafenib monohydrate | Ruxolitinib | Sorafenib | Resveratrol | Dasatinib | Pexidartinib | Regorafenib | Brigatinib | Lenvatinib | Pazopanib | Lentinan |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Hematonosis Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
